Answers are grounded in this paper and cite their sources.
Ganoderic acids are the primary bioactive constituents of the medicinal fungus Ganoderma lucidum. Commercial cultivars typically have low ganoderic triterpenoid contents, creating an urgent industry need for high-triterpenoid germplasm. Here, we developed an efficient breeding pipeline for G. lucidum using protoplasts of strain 'Xianzhi No. 2' subjected to sodium azide (SA) mutagenesis, followed by antagonistic screening and total triterpenoid quantification to identify elite mutants. SA concentrations of 0–5 mM were tested, and 2 mM was selected as the half-lethal dose (53.30% ± 8.61% protoplast survival after 3 h treatment) for mutant library construction. Mutagenized isolates were categorized into five categories (I–V) by antagonistic phenotype. From 4,839 colonies, 217 with distinct antagonistic traits, and 259 randomly selected non-antagonistic isolates were cultivated for fruiting body production, yielding 275 fruiting-competent mutants. Quantitative analysis revealed that the high-yield mutant TT89 had a total triterpenoid content of 4.40%, a 262.27% increase over the wild-type (1.68% content). We also identified mutants with significantly reduced triterpenoid levels, including the non-antagonistic strain X16, which contained only 16.34% of the wild-type's triterpenoid content. This is the first report of an integrated breeding system for G. lucidum combining SA mutagenesis, antagonistic prescreening, and triterpenoid quantification. Our findings validate SA as an effective mutagen for G. lucidum and provide valuable mutant resources and technical support for germplasm improvement and triterpenoid biosynthesis research.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: